1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma
    Journal Article

    Motzer, R. J.; Haas, N. B.; Donskov, F.; Gross-Goupil, M.; Varlamov, S.; Kopyltsov, E.; Lee, J. L.; Melichar, B.; Rini, B. I.; Choueiri, T. K.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Perioperative management of localized kidney cancer: Watching and waiting
    Journal Article

    Voss, M. H.; Motzer, R. J.
    JAMA Oncology (2017)

    Fulltext@MSK | Save
  • Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy
    Journal Article

    Beltran, H.; Wyatt, A. W.; Chedgy, E. C.; Donoghue, A.; Annala, M.; Warner, E. W.; Beja, K.; Sigouros, M.; Mo, F.; Fazli, L.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition
    Journal Article

    Yaeger, R.; Yao, Z.; Hyman, D. M.; Hechtman, J. F.; Vakiani, E.; Zhao, H.; Su, W.; Wang, L.; Joelson, A.; Cercek, A.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Aberrant activation of a gastrointestinal transcriptional circuit in prostate cancer mediates castration resistance
    Journal Article

    Shukla, S.; Cyrta, J.; Murphy, D. A.; Walczak, E. G.; Ran, L.; Agrawal, P.; Xie, Y.; Chen, Y.; Wang, S.; Zhan, Y.; more...
    Cancer Cell (2017)

    Fulltext@MSK | Save
  • The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies
    Journal Article

    Slovin, S. F.
    Biomarkers in Medicine (2017)

    Fulltext@MSK | Save
  • A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
    Journal Article

    Voss, M. H.; Hussain, A.; Vogelzang, N.; Lee, J. L.; Keam, B.; Rha, S. Y.; Vaishampayan, U.; Harris, W. B.; Richey, S.; Randall, J. M.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Mapping the functional landscape of ERCC2 mutations in muscle-invasive bladder cancer
    Meeting Abstract

    Frazier, Z.; Damish, A.; Reznichenko, E.; Liu, D.; Rosenberg, J.; Van Allen, E.; Lazaro, J. B.; D'Andrea, A. D.; Mouw, K.
    International Journal of Radiation Oncology, Biology, Physics (2017)

    Fulltext@MSK | Save
  • Overall survival (OS) in METEOR, a randomised phase III trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Mainwaring, P.; Powles, T.; Escudier, B. J.; Tannir, N. M.; Rini, B. I.; Hammers, H. J.; Donskov, F.; Roth, B. J.; Peltola, K.; Lee, J. L.; more...
    Asia-Pacific Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
    Meeting Abstract

    Krieger, L.; Shapiro, J.; Byard, I.; Campbell, D.; Clay, T.; Ganju, V.; Watkins, S.; Simmons, A.; Go, J.; Shetty, S.; more...
    Asia-Pacific Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save